Respiratory viral diseases: access to RNA interference therapy

This review summarizes recent experimental achievements in the area of the development of new RNA interference (RNAi) therapeutics for the treatment of viral respiratory diseases. Delivery of short interfering RNA (siRNA) to their intended target tissue remains the biggest problem for most therapeut...

Descripción completa

Detalles Bibliográficos
Autores principales: Bitko, Vira, Barik, Sailen
Formato: Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2007
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2597863/
https://www.ncbi.nlm.nih.gov/pubmed/19081824
http://dx.doi.org/10.1016/j.ddstr.2008.01.001
_version_ 1782161903706963968
author Bitko, Vira
Barik, Sailen
author_facet Bitko, Vira
Barik, Sailen
author_sort Bitko, Vira
collection PubMed
description This review summarizes recent experimental achievements in the area of the development of new RNA interference (RNAi) therapeutics for the treatment of viral respiratory diseases. Delivery of short interfering RNA (siRNA) to their intended target tissue remains the biggest problem for most therapeutic applications of these compounds. Appropriate formulations and chemical modifications for improved stability will boost the probability of utilization of RNAi drugs in the clinical applications.
format Text
id pubmed-2597863
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-25978632008-12-09 Respiratory viral diseases: access to RNA interference therapy Bitko, Vira Barik, Sailen Drug Discov Today Ther Strateg Article This review summarizes recent experimental achievements in the area of the development of new RNA interference (RNAi) therapeutics for the treatment of viral respiratory diseases. Delivery of short interfering RNA (siRNA) to their intended target tissue remains the biggest problem for most therapeutic applications of these compounds. Appropriate formulations and chemical modifications for improved stability will boost the probability of utilization of RNAi drugs in the clinical applications. Elsevier Ltd. 2007 2008-02-20 /pmc/articles/PMC2597863/ /pubmed/19081824 http://dx.doi.org/10.1016/j.ddstr.2008.01.001 Text en Copyright © 2008 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Bitko, Vira
Barik, Sailen
Respiratory viral diseases: access to RNA interference therapy
title Respiratory viral diseases: access to RNA interference therapy
title_full Respiratory viral diseases: access to RNA interference therapy
title_fullStr Respiratory viral diseases: access to RNA interference therapy
title_full_unstemmed Respiratory viral diseases: access to RNA interference therapy
title_short Respiratory viral diseases: access to RNA interference therapy
title_sort respiratory viral diseases: access to rna interference therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2597863/
https://www.ncbi.nlm.nih.gov/pubmed/19081824
http://dx.doi.org/10.1016/j.ddstr.2008.01.001
work_keys_str_mv AT bitkovira respiratoryviraldiseasesaccesstornainterferencetherapy
AT bariksailen respiratoryviraldiseasesaccesstornainterferencetherapy

Ejemplares similares